Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Every story we pull is tagged to the disease it’s about — so you can filter to your condition and read only what matters.
20 earlier
lanreotide a somatostatin analogue in advanced merkel cell carcinoma a prospective single arm phase ii study
Original title: “Lanreotide, a Somatostatin Analogue, in Advanced Merkel Cell Carcinoma: A Prospective Single-Arm Phase II Study.”
Adaptive Clinical Trial Design ... Ketamine Therapy Oncology Trials Opinion Parkinson's Disease Platform Trials Psilocybin MDMA Psychedelic Clinical Trials PSYCH PULSE Real-World Evidence site activation Site Operations study startup Treatment-Resistant Depression ... Fewer than 5% of the more than 10,000 known rare diseases have ... Adaptive Clinical Trial Design Adaptive Trial Design Addiction Psychiatry AI in Clinical Trials alcohol use disorder Alzheimer's Disease Article Clinical Operations Clinical Research Clinical Trial Design Clinical Trial Operations Clinical Trial Ops Brief Clinical Trials CLINOPS WATCHDOG CNS Drug Development CNS Trials Conference Coverage Decentralized Clinical Trials Digital Health Technologies dual diagnosis eClinical Tech News eClinical Technology EMA Executive Interviews FDA Enforcement FDA Guidance FDA Real-World Evidence FDA Regulation FDA Regulatory Strategy FDA Warning Letter GCP Compl Five compounding barriers—awareness, protocol complexity, competition, hesitancy, and logistics—block rare disease patient enrollment in clinical trials. The FDA’s own guidance on enhancing clinical trial participation calls out the particular pressure rare disease programs face: when the eligible population numbers in the hundreds nationally, a single site that fails to communicate clearly can cost the study months. The hesitancy barrier deserves specific attention because it is easy to misread. In rare disease, many patients arrived at their current treatment regimen after years of misdiagnosis and failed options. Source link: https://www.medpace.com/blog/overcoming-the-greatest-barriers-in-rare-disease-patient-recruitment/ ... Moe Alsumidaie, MBA, MSF, is founder and Chief Editor of Vanguard Publications, which publishes Clinical Trial Vanguard, Pharma Vanguard and BullScope, and Head of Research at CliniBiz.
Original title: “Five Barriers Block Rare Disease Patient Enrollment in Clinical Trials”
Adaptive Clinical Trial Design ... Ketamine Therapy Oncology Trials Opinion Parkinson's Disease Platform Trials Psilocybin MDMA Psychedelic Clinical Trials PSYCH PULSE Real-World Evidence site activation Site Operations study startup Treatment-Resistant Depression ... Fewer than 5% of the more than 10,000 known rare diseases have ... Adaptive Clinical Trial Design Adaptive Trial Design Addiction Psychiatry AI in Clinical Trials alcohol use disorder Alzheimer's Disease Article Clinical Operations Clinical Research Clinical Trial Design Clinical Trial Operations Clinical Trial Ops Brief Clinical Trials CLINOPS WATCHDOG CNS Drug Development CNS Trials Conference Coverage Decentralized Clinical Trials Digital Health Technologies dual diagnosis eClinical Tech News eClinical Technology EMA Executive Interviews FDA Enforcement FDA Guidance FDA Real-World Evidence FDA Regulation FDA Regulatory Strategy FDA Warning Letter GCP Compl Five compounding barriers—awareness, protocol complexity, competition, hesitancy, and logistics—block rare disease patient enrollment in clinical trials. The FDA’s own guidance on enhancing clinical trial participation calls out the particular pressure rare disease programs face: when the eligible population numbers in the hundreds nationally, a single site that fails to communicate clearly can cost the study months. The hesitancy barrier deserves specific attention because it is easy to misread. In rare disease, many patients arrived at their current treatment regimen after years of misdiagnosis and failed options. Source link: https://www.medpace.com/blog/overcoming-the-greatest-barriers-in-rare-disease-patient-recruitment/ ... Moe Alsumidaie, MBA, MSF, is founder and Chief Editor of Vanguard Publications, which publishes Clinical Trial Vanguard, Pharma Vanguard and BullScope, and Head of Research at CliniBiz.
Original title: “Five Barriers Block Rare Disease Patient Enrollment in Clinical Trials”
In accordance with the requirements of the Privacy Act of 1974, as amended, the Department of Health and Human Services (HHS) is modifying an existing system of records maintained by the Office of Refugee Resettlement (ORR) within HHS' Administration for Children and Families (ACF), System No. 09-80-0321, ORR Unaccompanied Children Bureau (UCB) Administrative Program Records. The system of records covers records about unaccompanied children, their intended sponsors, and members of the intended s
Original title: “Privacy Act of 1974; System of Records”
Original title: “Agency Forms Undergoing Paperwork Reduction Act Review”
The Centers for Disease Control and Prevention (CDC), as part of its continuing effort to reduce public burden and maximize the utility of government information, invites the general public and other federal agencies the opportunity to comment on a proposed information collection, as required by the Paperwork Reduction Act of 1995. This notice invites comment on a proposed information collection project titled Public Health Emergency Preparedness (PHEP) Cooperative Agreement. This request propos
Original title: “Proposed Data Collection Submitted for Public Comment and Recommendations”
The Centers for Disease Control and Prevention (CDC), as part of its continuing effort to reduce public burden and maximize the utility of government information, invites the general public and other federal agencies the opportunity to comment on a continuing information collection, as required by the Paperwork Reduction Act of 1995. This notice invites comment on a proposed information collection project titled Colorectal Cancer Control Program (CRCCP) Monitoring Activities. CDC is requesting a
Original title: “Proposed Data Collection Submitted for Public Comment and Recommendations”
In compliance with the Paperwork Reduction Act of 1995, the National Institutes of Health (NIH) has submitted to the Office of Management and Budget (OMB) a request for review and approval of the information collection listed below.
Original title: “Submission for OMB Review; 30-Day Comment Request; Generic Clearance for NIH Citizen Science and Crowdsourcing Projects (Office of the Director)”
In compliance with the Paperwork Reduction Act of 1995, the National Institutes of Health (NIH) has submitted to the Office of Management and Budget (OMB) a request for review and approval of the information collection listed below.
Original title: “Submission for OMB Review; 30-Day Comment Request;”
recognition and treatment of concurrent amyotrophic lateral sclerosis and multiple sclerosis
Original title: “Recognition and Treatment of Concurrent Amyotrophic Lateral Sclerosis and Multiple Sclerosis.”
mucinous adenocarcinoma arising in a mature ovarian teratoma
Original title: “Mucinous Adenocarcinoma Arising in a Mature Ovarian Teratoma.”
ep547 mrgprx4 inverse agonist for cholestatic pruritus due to primary biliary cholangitis or primary sclerosing cholangitis results from the phase 2 randomized placebo controlled pacific study
Original title: “EP547 (MRGPRX4 inverse agonist) for cholestatic pruritus due to primary biliary cholangitis or primary sclerosing cholangitis: Results from the phase 2 randomized, placebo-controlled PACIFIC study.”
case of graft versus host disease in a liver transplant recipient receiving an hcv nat positive organ does hcv nat matter
Original title: “A Case of Graft-Versus-Host Disease in a Liver Transplant Recipient Receiving an HCV NAT Positive Organ: Does HCV NAT Matter?”
concurrent follicular lymphoma and follicular dendritic cell sarcoma composite neoplasm or transdifferentiation
Original title: “Concurrent follicular lymphoma and follicular dendritic cell sarcoma: composite neoplasm or transdifferentiation?”
clinicopathological spectrum and outcomes of biopsy proven post transplant lymphoproliferative disorder after kidney transplantation
Original title: “Clinicopathological spectrum and outcomes of biopsy-proven post-transplant lymphoproliferative disorder after kidney transplantation.”
when standard rectal cancer treatment conflicts with pregnancy preservation a multidisciplinary clinical challenge
Original title: “When standard rectal cancer treatment conflicts with pregnancy preservation: a multidisciplinary clinical challenge.”
post transfusion purpura pathogenic mechanisms and relationship with immune thrombocytopenia a critical analytical review
Original title: “Post-transfusion purpura: pathogenic mechanisms and relationship with immune thrombocytopenia: a critical analytical review.”